Jos H. Beijnen

75.3k total citations · 8 hit papers
1.5k papers, 57.9k citations indexed

About

Jos H. Beijnen is a scholar working on Oncology, Molecular Biology and Pharmacology. According to data from OpenAlex, Jos H. Beijnen has authored 1.5k papers receiving a total of 57.9k indexed citations (citations by other indexed papers that have themselves been cited), including 764 papers in Oncology, 462 papers in Molecular Biology and 203 papers in Pharmacology. Recurrent topics in Jos H. Beijnen's work include Drug Transport and Resistance Mechanisms (256 papers), Cancer Treatment and Pharmacology (242 papers) and Cancer therapeutics and mechanisms (201 papers). Jos H. Beijnen is often cited by papers focused on Drug Transport and Resistance Mechanisms (256 papers), Cancer Treatment and Pharmacology (242 papers) and Cancer therapeutics and mechanisms (201 papers). Jos H. Beijnen collaborates with scholars based in Netherlands, United States and United Kingdom. Jos H. Beijnen's co-authors include Jan H.M. Schellens, Hilde Rosing, Alwin D. R. Huitema, Olaf van Tellingen, Alfred H. Schinkel, Piet Borst, Rolf W. Sparidans, Els Wagenaar, W.W. ten Bokkel Huinink and Dick Pluim and has published in prestigious journals such as New England Journal of Medicine, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Jos H. Beijnen

1.4k papers receiving 56.4k citations

Hit Papers

Disruption of the mouse mdr1a P-glycoprotein gene leads t... 1994 2026 2004 2015 1994 2004 1997 2002 2012 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs
    1994 1.8k citations Alfred H. Schinkel, Olaf van Tellingen et al. profile →
  2. A Phase I and Pharmacological Study with Imidazolium- trans- DMSO-imidazole-tetrachlororuthenate, a Novel Ruthenium Anticancer Agent
    2004 760 citations Dick Pluim, Jos H. Beijnen et al. Clinical Cancer Research profile →
  3. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
    1997 749 citations Ulrich Mayer, Alfred H. Schinkel et al. profile →
  4. The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria
    2002 672 citations Els Wagenaar, Hilde Rosing et al. profile →
  5. Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis
    2012 573 citations Thomas P. C. Dorlo, Jos H. Beijnen et al. Journal of Antimicrobial Chemotherapy profile →
  6. Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies
    2010 558 citations Alwin D. R. Huitema, Jan H.M. Schellens et al. profile →
  7. Approaching tumour therapy beyond platinum drugs
    2011 450 citations Jan H.M. Schellens, Jos H. Beijnen et al. profile →
  8. Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors
    2019 404 citations Jos H. Beijnen, Jan H.M. Schellens et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jos H. Beijnen Netherlands 111 27.4k 17.7k 7.5k 6.0k 6.0k 1.5k 57.9k
Michael M. Gottesman United States 101 32.9k 1.2× 27.8k 1.6× 7.8k 1.0× 3.1k 0.5× 2.2k 0.4× 408 53.6k
Alfred H. Schinkel Netherlands 88 22.2k 0.8× 8.7k 0.5× 10.6k 1.4× 4.0k 0.7× 1.5k 0.3× 297 30.8k
Jan H.M. Schellens Netherlands 91 22.6k 0.8× 16.1k 0.9× 3.2k 0.4× 3.6k 0.6× 6.4k 1.1× 882 41.1k
Matthias Schwab Germany 95 9.2k 0.3× 8.6k 0.5× 6.4k 0.9× 8.7k 1.4× 2.6k 0.4× 792 45.9k
Yuichi Sugiyama Japan 99 25.4k 0.9× 7.8k 0.4× 13.0k 1.7× 11.2k 1.8× 877 0.1× 831 40.4k
Alex Sparreboom United States 86 14.2k 0.5× 8.9k 0.5× 3.3k 0.4× 3.3k 0.5× 2.7k 0.5× 408 24.4k
Anthony Cerami United States 135 6.5k 0.2× 18.8k 1.1× 2.0k 0.3× 1.2k 0.2× 4.3k 0.7× 514 76.7k
Zhe‐Sheng Chen United States 90 12.7k 0.5× 15.5k 0.9× 2.1k 0.3× 1.1k 0.2× 2.6k 0.4× 591 31.1k
Elisabeth G.E. de Vries Netherlands 102 24.1k 0.9× 14.3k 0.8× 2.4k 0.3× 663 0.1× 7.4k 1.2× 1.0k 47.8k
Mary V. Relling United States 97 7.6k 0.3× 8.6k 0.5× 12.3k 1.6× 7.4k 1.2× 1.7k 0.3× 381 33.5k

Countries citing papers authored by Jos H. Beijnen

Since Specialization
Citations

This map shows the geographic impact of Jos H. Beijnen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jos H. Beijnen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jos H. Beijnen more than expected).

Fields of papers citing papers by Jos H. Beijnen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jos H. Beijnen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jos H. Beijnen. The network helps show where Jos H. Beijnen may publish in the future.

Co-authorship network of co-authors of Jos H. Beijnen

This figure shows the co-authorship network connecting the top 25 collaborators of Jos H. Beijnen. A scholar is included among the top collaborators of Jos H. Beijnen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jos H. Beijnen. Jos H. Beijnen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Nijenhuis, Cynthia M., Inge Jedema, Justin T. Moyers, et al.. (2025). Defining the Quality Attributes for Tumor-Infiltrating Lymphocyte Medicinal Products. Transplantation and Cellular Therapy. 31(3). S610–S625. 3 indexed citations
2.
Sparidans, Rolf W., et al.. (2024). The ABCB1 and ABCG2 efflux transporters limit brain disposition of the SYK inhibitors entospletinib and lanraplenib. Toxicology and Applied Pharmacology. 485. 116911–116911. 2 indexed citations
3.
Sundar, Shyam, Dinesh Mondal, Murari Lal Das, et al.. (2024). Skin pharmacokinetics of miltefosine in the treatment of post-kala-azar dermal leishmaniasis in South Asia. Journal of Antimicrobial Chemotherapy. 79(7). 1547–1554. 1 indexed citations
4.
5.
Rosing, Hilde, Wenlong Li, Els Wagenaar, et al.. (2024). Intestinal human carboxylesterase 2 (CES2) expression rescues drug metabolism and most metabolic syndrome phenotypes in global Ces2 cluster knockout mice. Acta Pharmacologica Sinica. 46(3). 777–793. 2 indexed citations
6.
Beijnen, Jos H., et al.. (2023). The use of microtracers in food‐effect trials: An alternative study design for toxic drugs with long half‐lives exemplified by the case for alectinib. Clinical and Translational Science. 16(12). 2557–2564. 2 indexed citations
7.
Tibben, Matthijs M., et al.. (2021). Simultaneous quantification of abemaciclib and its active metabolites in human and mouse plasma by UHPLC–MS/MS. Journal of Pharmaceutical and Biomedical Analysis. 203. 114225–114225. 18 indexed citations
8.
Bakker, Noor A. M., Renate de Boer, Corinne Marie, et al.. (2019). Small-scale GMP production of plasmid DNA using a simplified and fully disposable production method. Journal of Biotechnology. 306. 100007–100007. 13 indexed citations
9.
Hoppe, Stéphanie van, Rolf W. Sparidans, Els Wagenaar, Jos H. Beijnen, & Alfred H. Schinkel. (2017). Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-gp/ABCB1) transport afatinib and restrict its oral availability and brain accumulation. Pharmacological Research. 120. 43–50. 47 indexed citations
10.
11.
12.
Henricks, Linda M., Jan H.M. Schellens, Alwin D. R. Huitema, & Jos H. Beijnen. (2015). The use of combinations of monoclonal antibodies in clinical oncology. Cancer Treatment Reviews. 41(10). 859–867. 73 indexed citations
13.
Lin, Fan, Serena Marchetti, Dick Pluim, et al.. (2013). Abcc4 Together with Abcb1 and Abcg2 Form a Robust Cooperative Drug Efflux System That Restricts the Brain Entry of Camptothecin Analogues. Clinical Cancer Research. 19(8). 2084–2095. 38 indexed citations
14.
Waterschoot, Robert A.B. van, Jurjen S. Lagas, Els Wagenaar, et al.. (2010). Individual and combined roles of CYP3A, P‐glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) in the pharmacokinetics of docetaxel. International Journal of Cancer. 127(12). 2959–2964. 44 indexed citations
15.
Lagas, Jurjen S., Robert A.B. van Waterschoot, Rolf W. Sparidans, et al.. (2010). Breast Cancer Resistance Protein and P-glycoprotein Limit Sorafenib Brain Accumulation. Molecular Cancer Therapeutics. 9(2). 319–326. 151 indexed citations
16.
Boss, David S., Dick Pluim, Hilde Rosing, et al.. (2009). Phase I Pharmacokinetic and Pharmacodynamic Study of Carboplatin and Topotecan Administered Intravenously Every 28 Days to Patients with Malignant Solid Tumors. Clinical Cancer Research. 15(13). 4475–4483. 1 indexed citations
17.
Lagas, Jurjen S., Rolf W. Sparidans, Robert A.B. van Waterschoot, et al.. (2008). P-Glycoprotein Limits Oral Availability, Brain Penetration, and Toxicity of an Anionic Drug, the Antibiotic Salinomycin. Antimicrobial Agents and Chemotherapy. 52(3). 1034–1039. 52 indexed citations
18.
Gast, Marie‐Christine W., Harm van Tinteren, M. Bontenbal, et al.. (2008). Haptoglobin phenotype is not a predictor of recurrence free survival in high-risk primary breast cancer patients. BMC Cancer. 8(1). 389–389. 24 indexed citations
19.
Lagas, Jurjen S., Cornelia M.M. van der Kruijssen, Koen van de Wetering, Jos H. Beijnen, & Alfred H. Schinkel. (2008). Transport of Diclofenac by Breast Cancer Resistance Protein (ABCG2) and Stimulation of Multidrug Resistance Protein 2 (ABCC2)-Mediated Drug Transport by Diclofenac and Benzbromarone. Drug Metabolism and Disposition. 37(1). 129–136. 60 indexed citations
20.
Wijnholds, Jan, Raymond Evers, Carla A.A.M. Mol, et al.. (1997). Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein. Nature Medicine. 3(11). 1275–1279. 364 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael M. Gottesman Breakdown of academic impact, for papers by Alfred H. Schinkel Breakdown of academic impact, for papers by Jan H.M. Schellens Breakdown of academic impact, for papers by Matthias Schwab Breakdown of academic impact, for papers by Yuichi Sugiyama Breakdown of academic impact, for papers by Alex Sparreboom Breakdown of academic impact, for papers by Anthony Cerami Breakdown of academic impact, for papers by Zhe‐Sheng Chen Breakdown of academic impact, for papers by Elisabeth G.E. de Vries Breakdown of academic impact, for papers by Mary V. Relling
Rankless by CCL
2026